FiercePharmaOriginal article
{"a":[{"_":"ESC: Amgen CMO flags Repatha 'inflection' amid new data on mortality benefit","$":{"href":"/pharma/esc-amgen-cmo-flags-repatha-inflection-mortality-data-headline-cardiology-conference-outing","hreflang":"en"}}]}
Data ReadoutpositiveRepathaPositive
AI Analysis
Summary
Amgen presented new mortality benefit data for Repatha (evolocumab), its PCSK9 inhibitor, at the ESC conference, signaling an inflection point for the 11-year-old cardiovascular risk reduction drug.
Outcome Details
New mortality benefit data presented at ESC conference
Importance:6/10
Sentiment:
0.70
cardiovascularPCSK9 inhibitormortality benefitESC conferenceestablished product
Related Companies
Read the original article
Published by FiercePharma on September 2, 2026 12:58 PM